The VA's GLP-1 trial for alcohol use disorder
The Department of Veterans Affairs launched a clinical trial in 2024 testing semaglutide for alcohol use disorder. Researchers enrolled veterans with both heavy drinking patterns and metabolic concerns. The study tracks changes in alcohol craving alongside body weight. Early signals suggest semaglutide may reduce alcohol intake independently of weight loss. This dual effect has caught the attention of researchers working on stubborn belly fat. A subset of GLP-1 users sees little change in abdominal adiposity. For them, the VA trial hints at pathways beyond appetite suppression.
Semaglutide acts on GLP-1 receptors in the brain and gut. The VA trial explores whether those same receptors shift reward processing for alcohol. If confirmed, the mechanism would involve dopamine modulation in mesolimbic circuits. That same circuitry influences stress-related eating and visceral fat storage. Researchers now ask whether a GLP-1 plus a lipolytic peptide could address non-response.
Tirzepatide, a dual GIP/GLP-1 agonist, shows stronger weight loss than semaglutide in trials. Yet even tirzepatide leaves some users with persistent central adiposity. A 2023 analysis found that roughly 15% of tirzepatide users lost less than 5% of baseline weight. Among those, belly fat reduction was minimal. The VA trial's focus on brain-reward pathways provides a new lens. It suggests that non-responders may need a compound that directly mobilizes fat stores. AOD-9604, a fragment of human growth hormone, has that lipolytic profile.
Why stubborn belly fat resists GLP-1s
Visceral fat is metabolically distinct from subcutaneous fat. It has more glucocorticoid receptors and a richer blood supply. Cortisol drives its accumulation, especially during chronic stress. GLP-1 agonists reduce caloric intake but do not directly counter cortisol's effects. In the luteal phase of the menstrual cycle, progesterone raises core temperature and can increase cortisol sensitivity. Some women notice belly fat retention despite steady tirzepatide dosing. A 2021 review noted that female participants in GLP-1 trials often report cycle-related weight fluctuations. This hormonal context matters for non-responders.
During the follicular phase, estrogen improves insulin sensitivity. GLP-1s tend to work more smoothly then. In the luteal phase, insulin resistance rises and cravings intensify. A woman using tirzepatide might see scale progress stall for two weeks each cycle. Over months, that pattern can mask true fat loss. Researchers caution against extrapolating male-only data to female physiology. Most early GLP-1 trials enrolled predominantly male cohorts. The VA trial includes both sexes, but its primary endpoint is alcohol use, not fat distribution.
AOD-9604 works through a different mechanism. It mimics the lipolytic portion of growth hormone without affecting IGF-1 or blood sugar. In rodent models, it increased fat oxidation and reduced visceral adiposity. Human trials remain limited. A 2014 study found modest reductions in abdominal fat with daily oral AOD-9604. The peptide does not suppress appetite. It targets fat breakdown directly. For a tirzepatide user stuck at a plateau, adding a lipolytic agent could address the cortisol-driven fat that GLP-1s leave untouched.
What the VA trial means for non-responders
The VA trial's design separates metabolic effects from behavioral ones. Participants receive semaglutide or placebo while undergoing standard alcohol counseling. If semaglutide reduces drinking through reward-pathway changes, it implies GLP-1s can alter deeply ingrained behaviors. For stubborn belly fat, that behavioral piece is often missing. Stress eating, sleep disruption, and alcohol itself contribute to visceral adiposity. Tirzepatide curbs appetite, but it does not erase the habit of reaching for food under stress. AOD-9604 cannot fix that either. The synergy lies in combining behavioral dampening with direct lipolysis.
Non-responders often have higher baseline cortisol or a history of yo-yo dieting. Their fat cells may be more resistant to catecholamine-induced lipolysis. AOD-9604 stimulates lipolysis through a different pathway, independent of beta-adrenergic receptors. In theory, it could mobilize fat even when endogenous signals are blunted. Researchers are watching the VA trial for secondary outcomes like waist circumference. If semaglutide reduces central adiposity beyond what calorie restriction predicts, the case for combination therapy strengthens.
Cycle-aware framing is essential here. A woman in her luteal phase might interpret a two-week stall as treatment failure. She might increase her tirzepatide dose prematurely. Understanding that progesterone-driven water retention and cortisol spikes are normal can prevent overreaction. Adding AOD-9604 during the luteal phase is an area of active inquiry. No published trials have tested this protocol. Anecdotal reports from research communities describe smoother fat loss across the cycle. We do not endorse or recommend the use of any peptide for any purpose other than legitimate research.
Who is affected most
Postpartum women and perimenopausal women face unique challenges with belly fat. After childbirth, abdominal muscles and skin have stretched. Fat deposited during pregnancy often lingers. Tirzepatide can help, but the hormonal shifts of breastfeeding or weaning complicate dosing. A 2022 review highlighted that GLP-1s are not studied during lactation. AOD-9604's safety profile in that context is unknown. Researchers urge caution.
Perimenopause brings erratic estrogen and progesterone levels. Some cycles are anovulatory, meaning no progesterone rise. Others have exaggerated luteal phase symptoms. Belly fat accumulation accelerates in these years. Tirzepatide users in perimenopause may see inconsistent results month to month. The VA trial's insights into reward pathways could explain why some women in this group respond poorly. Alcohol use often increases during perimenopause, compounding metabolic stress. A combination approach might address both the hormonal and behavioral drivers.
Men with high stress occupations also fit the non-responder profile. First responders, military personnel, and executives often have elevated cortisol. The VA trial specifically enrolls veterans, a population with high rates of PTSD and alcohol use. Their response to semaglutide could inform protocols for civilians with similar stress burdens. Tirzepatide's dual agonism may offer an advantage here, but the data are still emerging. Retatrutide, a triple agonist, is in phase 3 trials and may further shift the landscape.
Practical considerations and costs
Tirzepatide compounding costs have fluctuated after recent FDA warnings. A month's supply from a compounding pharmacy can run $300 to $500. Brand-name Mounjaro is often over $1,000 without insurance. AOD-9604 is sold as a research peptide, typically in 5 mg vials. Prices range from $48 to $80 per vial. A common research protocol uses 300 mcg daily, making a vial last about 16 days. That puts monthly costs around $90 to $150. Combining the two could push monthly expenses to $400–$650. Researchers must weigh that against potential benefits.
Semaglutide compounding demand surged after an FDA panel vote in 2024. Shortages led some researchers to explore AOD-9604 as a bridge during gaps in GLP-1 supply. That approach is detailed in a recent article on semaglutide compounding demand. The logic applies to tirzepatide as well. When tirzepatide is unavailable, AOD-9604 might maintain some lipolytic activity. It does not replace the appetite suppression, but it could prevent rapid fat regain. Another article on tirzepatide compounding risks discusses plateaus and the addition of CJC-1295. CJC-1295 increases growth hormone pulses, potentially amplifying AOD-9604's effects. However, that combination raises IGF-1, which requires careful monitoring.
Hexarelin, a growth hormone secretagogue, is sometimes mentioned alongside AOD-9604. It strongly stimulates GH release but can elevate cortisol and prolactin. For someone with already high cortisol, hexarelin might worsen belly fat. Researchers generally avoid it in stress-related adiposity. The safer research path pairs AOD-9604 with a GLP-1 agonist alone. Cycle timing adds another layer. A researcher might administer AOD-9604 only during the luteal phase to target cortisol-driven fat storage. That protocol remains experimental.
What to watch next
The VA trial is expected to publish initial results in late 2025. Secondary analyses on body composition will be particularly informative. If semaglutide reduces visceral fat independently of weight loss, it will validate the brain-fat axis hypothesis. Tirzepatide researchers will likely follow with similar endpoints. A trial combining tirzepatide and a lipolytic peptide has not been announced, but the rationale is growing. The FDA's stance on compounding may also shift. Recent warnings have tightened access to tirzepatide and semaglutide from compounding pharmacies. Researchers relying on these sources face uncertainty.
Menstrual changes on semaglutide have been reported by some users. A dedicated article on semaglutide menstrual changes explores whether AOD-9604 can help. The interaction between GLP-1s and the menstrual cycle is understudied. Future trials should stratify by cycle phase and menopausal status. Until then, researchers must extrapolate cautiously from available data. Another area to watch is the GI risk when restarting tirzepatide after a break. A recent article on tirzepatide vs semaglutide GI risk covers this topic. Non-responders who pause treatment may face heightened side effects upon resumption. AOD-9604 does not cause GI distress, making it a potential tool during washout periods.
Retatrutide's phase 3 trials include body composition endpoints. It adds glucagon agonism, which directly stimulates lipolysis. If approved, it could reduce the need for add-on peptides like AOD-9604. However, glucagon agonism can raise blood glucose, a concern for some users. Tirzepatide avoids this by balancing GIP and GLP-1. The peptide research community will continue to explore combinations that fill the gaps left by single agents. Stubborn belly fat remains a challenge, but the VA trial opens a new chapter. It connects metabolic health, brain reward, and stress physiology in a way that could reshape treatment paradigms.
Mentions of brand or product names are for identification only and do not constitute endorsement.